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A B S T R A C T
Hypoxia is part of the tumor microenvironment favoring cancer resistance to chemotherapy mediated by
mutations in the tumor suppressor p53 gene (TP53), or by conformational wt TP53 dysfunction. Since it
is important to suppress tumor adaptation to hypoxia, irrespective of p53 status, we compared the
efﬁcacy of nutlin-3 which prevents MDM2-wt p53 interactions and PRIMA-1 which promotes mutant
p53 reactivation and induction of massive apoptosis, under normoxia and hypoxia, against (a) SKBR3
breast carcinoma harboring a mutant p53R175H and over-expressing erbB2; and (b) genetically
matched breast cancer ERa positive MCF-7 cells harboring either wt p53 or mutant p53 R175H. Under
normoxia, PRIMA-1 was active against breast cancer cells harboring mutant p53. However, hypoxia
further increased the susceptibility of mutant p53 breast cancer SKBR3 cells to lower PRIMA-1 levels,
possibly through oxidative stress since this was counteracted by N-acetylcysteine. When using MCF-7
cells over-expressing mutant p53, PRIMA-1 synergized with exogenous peroxidase to increase apoptosis
concomitantly with induction of PUMA and Mn-SOD, under normoxia. Wt p53 MCF-7 cells responded to
hypoxia by increasing superoxide dismutase and their reactivity with the PAb240 antibody, known to
recognize conformationally-inactive p53. This correlated with sensitization of wt p53 MCF-7 cells to
PRIMA-1 but not to nutlin-3. PRIMA-1 toxicity against normoxic wt p53 MCF-7 cells was also decreased
by Mn-SOD over-expression or when added with the glutathione antagonist, buthionine sulfoximine.
This report shows for the ﬁrst time that hypoxia increases PRIMA-1 toxicity in human breast cancer cells,
partly by modulating p53 conformation and by inducing superoxide turnover. Our results suggest that
PRIMA-1 may help to prevent hypoxia-mediated tumor chemoresistance.
 2012 Elsevier Inc. 
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During cancer progression, tumor cells face a progressively
hypoxic and hypoglycemic microenvironment when growing
distant from sites of vascularization [1,2]. Hypoxia originates a
gradient of oxidative stress mediated by H2O2 capable of
promoting cancer cell heterogeneity, by enhancing mutational
potential [2], which helps select cells with resistance to
conventional anti-tumor therapies [3–7]. Genomic instability of
cancer cells is frequently antagonized by activation of the tumor
suppressor protein encoded by the Tp53 gene, which is involved in
monitoring DNA damage to help induce growth arrest and DNAAbbreviations: DN-mutant p53 R175H, dominant-negative mutant p53 Arg 175His;
wt, wild type; PARP, poly(ADP-ribose) polymerase; [Mn-SOD, SOD2], manganese-
dependent superoxide dismutase; [Cu/Zn-SOD, SOD1], copper–zinc-dependent
superoxide dismutase; BSO, buthionine sulfoximine; ROS, reactive oxygen species;
NAC, N-acetylcysteine; GSH, glutathione.
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Open access under CC BY-NC-ND license.repair or apoptosis, to help maintain the integrity of genome [8,9].
Many cancer cells die in response to hypoxia because their high
metabolic requirements make them much more dependent on
glycolytic pathways which increase their glucose demands [10,11].
However, tumor cell adaptation to hypoxic stress partly occurs
because p53 tumor suppressive function may be compromised by
the stress induced by sub-optimal glucose and oxygen [12–14] or
by oxidative stress [15]. Hence, it is important to ﬁnd conditions to
enhance activation of wt p53 and to re-activate mutant p53 in
heterogeneous tumor cell populations, in which low oxygen and
oxidative imbalance could inactivate Tp53 either by mutation [8,9]
or conformational dysfunction [13–16]. The small molecule
PRIMA-1 [bis(hydroxymethyl)-3-quinuclidinone], was discovered
by its ability to promote mutant p53 reactivation and induction of
massive apoptosis in various cancer cells [17]. Although the effect
of PRIMA-1 and its analog PRIMA-1Met is frequently recognized as
speciﬁc for mutant p53 cells [17–22], more recently, PRIMA-1Met
was found effective against small cell lung carcinoma cells with
low or undetectable levels of mutant p53 [19]. In some breast
cancer cells, PRIMA-1 induced cell death in vitro and in vivo
in estrogen-responsive cell lines that express mt p53 (BT-474,
M. Rieber, M. Strasberg-Rieber / Biochemical Pharmacology 84 (2012) 1563–15701564HCC-1428, and T47-D) [20]. In contrast, PRIMA-1 had no effect on
the viability of MCF-7 cells, normal breast cells, and endothelial
cells, all of which express wild-type 53 protein [20]. PRIMA-1 also
induced apoptosis in human breast cancer cells MDA-MB-231 and
GI-101A, mediated by PUMA and Bax induction [21]. Although
several reports implied the selectivity of PRIMA-1 for mutant p53
cells, it was recently shown that PRIMA-1Met binds not only to
mutant p53, but it can also bind to unfolded wt p53 [22], with the
degree of binding correlating with the extent of unfolding,
implying that PRIMA-1Met may also activate unfolded wt p53
[22]. Since hypoglycemic/hypoxic condition mimicking in vitro the
tumor microenvironment markedly reduced the efﬁcacy of
anticancer drugs [1], we have now compared the hypoxic and
normoxic response of some human breast cancer cells to PRIMA-1
and to an alternative p53-reactivating drug, nutlin-3, known to act
by preventing wt p53 degradation by disrupting the p53–MDM2
interactions [23–26]. However, it is of interest that the ability of
nutlin-3 to activate p53 is compromised in tumor cells over-
expressing MDMX, like MCF-7 cells [24,25]. However, since nutlin-
3 radiosensitizes hypoxic prostate cancer cells independent of p53,
it seemed of interest to investigate how nutlin-3 and PRIMA-1
reacted against MCF-7 cells under hypoxia since this [10,12–14]
and oxidative stress [15] can induce an inactive conformation in wt
p53 [16]. Initially, we used SKBR3 breast carcinoma harboring
endogenous mutant p53R175H and erbB2//Her2 over-expression
[27,28]. These cells are important because of the human epidermal
growth factor receptor 2 (HER2) and p53 pathways may be
involved in breast cancer response to chemotherapy [29]. We also
investigated the responses to PRIMA-1 in genetically-matched
ERa+ human breast cancer MCF-7 cells expressing wt p53 or an
exogenous mutant p53R175H [30], and in wt p53 MCF-7 cells over-
expressing Mn-SOD and the corresponding vector-transfected cells
[31]. We also investigated whether hypoxia partly induced a
conformational unfolded p53 protein recognized by the monoclo-
nal antibody PAb240 (directed toward unfolded p53) [15,16].
Moreover, since it is important to improve the efﬁcacy of PRIMA-1
against mutant p53 SKBR3 breast carcinoma, we also studied
whether hypoxia also enhances their response to lower PRIMA-1
concentrations. Finally, since restriction of oxygen at may increase
superoxide metabolism [32], we also investigated whether these
conditions inﬂuence superoxide dismutase (SOD) expression.
2. Materials and methods
2.1. Cell lines
Experiments were performed with: (a) SKBR3 harboring
endogenous mutant p53R175H and erbB2//Her2 over-expression
[27–29]; (b) wt p53 MCF-7 human breast carcinoma neo4 cells,
obtained by transfection with control Neo-vector, and Mn-SOD-
over-expressing (Mn11-cells) transfected with Mn-SOD cDNA in
the same vector. These cells were cultured in Dulbecco’s medium
containing 10% fetal bovine serum, and G418 at 400 mg/ml. The
veriﬁcation of Mn-SOD over-expression for Mn11 cells was
previously described [31]. We appreciate the kind provision of
Mn11- and Neo-MCF-7 cells by Dr. L. Oberley, Free Radical and
Radiation Biology Program, Department of Radiation Oncology,
University of Iowa, Iowa City, Iowa, USA; (c) MCF-7 human breast
carcinoma cells which harbor a functional wt p53 or a mutant p53
R175H [30]. To obtain isogenic wt p53 or mutant p53 cells,
parental MCF-7 cells were transduced with plasmids (kindly
provided by Dr. Scott Lowe, Cold Spring Harbor Laboratory, New
York) packaged into Phoenix retroviral packaging cells (kindly
provided by Dr. Garry P. Nolan, Stanford University, CA). Phoenix
cells were transfected with the pWZL-Hygro plasmid harboring a
human p53 histidine-175 mutant gene, a dominant-negative (DN)p53 mutant plasmid, in the presence of calcium chloride. As
previously described [30], control cells were retrovirally transduced
with the empty pWZL-Hygro plasmid. Hygromycin (Calbiochem,
San Diego, CA) was used at a ﬁnal concentration of 100 mg/ml.
Veriﬁcation of conformationally inactive p53 was achieved by
immune precipitation of mutant p53 with monoclonal antibody Pab
240 (SC-99), p53 mutant-speciﬁc under nondenaturing conditions
or by staining cells ﬁxed with 4% p-formaldehyde in PBS, followed by
cell permeabilization with non-ionic detergents like octyl glucoside
or Nonidet P40 at 0.5%. Conformationally active wt p53 was
identiﬁed by lack of immune precipitation with Pab 240 (SC-99)
under nondenaturing immune precipitation and reactivity with
monoclonal antibody (DO-1; SC-126) under comparable conditions.
Immune precipitations were aided by the addition of protein A/G
Plus agarose (SC-2003). Precipitated proteins were subjected to SDS-
PAGE electrophoresis, bidirectionally blotted onto nitrocellulose
membranes and identiﬁed by DO-1 (SC-126) monoclonal antibody,
which recognizes both wt and mutant denatured p53’s. All
antibodies and protein A/G Plus agarose were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA).
2.2. Relative cellular metabolic activity
This was estimated with Alamar Blue (resazurin) obtained from
Life Technologies (Carlsbad, CA). It measures intracellular redox
mitochondrial activity by quantitating the cell-catalyzed conversion
of non-ﬂuorescent resazurin to ﬂuorescent resoruﬁn. For these
experiments, cells (10,000) were allowed to adhere overnight in 96
well TC microtiter dishes. After the corresponding treatments,
Alamar Blue was added to 10% of the cell volume without removing
medium containing dead cells, and ﬂuorescence was measured 4 h
later in a Labsystems Fluoroskan Ascent microplate reader at an
excitation of 544 nm and an emission of 590 nm [33].
2.3. Western blot analysis
Cells were harvested in PBS containing protease and phospha-
tase inhibitors using a rubber policeman. Extracts were prepared in
cell lysis buffer (50 mM Tris–HCl, pH 8, 120 mM NaCl, 50 mM NaF,
0.1 mM sodium vanadate, 5 mM EDTA, 10 mg/ml each of leupeptin,
soybean trypsin inhibitor, and aprotinin, 1 mM phenylmethylsul-
fonyl ﬂuoride, 0.4% Nonidet P40). Seventy-ﬁve micrograms of
protein was loaded into each well of a 11% SDS-polyacrylamide gel
and electrophoretically separated. After protein transfer, the
membranes were blocked with TBS (Tris-buffered saline, pH 7.5)
containing 0.1% Tween-20 and 5% nonfat skim milk. All the
chemicals above indicated were obtained from Sigma–Aldrich (St.
Louis, MO, USA). Antibody detecting both the intact and cleaved
PARP forms [33] and antibody versus actin were from Cell
Signaling (Waltham, MA, USA).
2.4. Crystal violet staining of surviving adherent cells
Cells were subjected to the treatments indicated in each case
under hypoxia or normoxia. Subsequently, the unattached dead
population was removed after washing twice in isotonic phosphate-
buffered saline. Surviving cells were evidenced following ﬁxation in
90% ethanol and cell staining with 0.5% crystal violet in 30% ethanol
(both from Sigma–Aldrich, St. Louis, MO, USA). Whenever indicated,
quantitation was achieved at 595 nm after eluting the dye in 30%
ethanol from quadruplicate stained cells [33].
2.5. Laser scanning cytometry
A laser scanning cytometer (LSC)-2 (Compucyte, Cambridge,
MA), which measures ﬂuorescence intensity of individual cells
Fig. 1. Hypoxia increases PRIMA-1 toxicity against SKBR3 breast cancer cells. Cultures were seeded in quadruplicate at 1  104 cells per 96 well plate overnight in complete
Dulbecco’s medium with 20 mM glucose supplemented with 10% fetal calf serum medium. The following day, cells were exposed to normoxia or hypoxia (1% oxygen)
including 0.1% DMSO (controls) or PRIMA-1 at the indicated concentrations in 0.1% DMSO. After 72 h, cells were ﬁxed in 70% ethanol followed by crystal violet staining, as
indicated under Section 2. Note the progressive loss of cell viability evidenced by decreased staining particularly evident in PRIMA-1 treated cells under hypoxia.
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propidium iodide was used. Every sample was scanned using
identical nonsaturating ﬂuorescence settings, to allow quantitative
comparisons to be made. To analyze ﬂuorescence changes on
individual cells, clustered aggregates were gated, so as to include
as many individual contoured cells as possible and quantitate
integral (total ﬂuorescence within the integral contour) and
maximal pixels (highest localized ﬂuorescence within the thresh-
old contour). After the indicated culture conditions, cells attached
to LabTek multiwell plates (Nunc-Nalge, Naperville, IL) pre-coated
with ﬁbronectin were ﬁxed in 4% paraformaldehyde in phosphate-
buffered saline (PBS), followed by permeabilization with 0.25%
Nonidet P40, washing in PBS, blocking in 5% albumin (in PBS). All
these reagents were obtained from Sigma–Aldrich (St. Louis, MO).
After ﬁxation and permeabilization, cells were reacted with either:
(i) monoclonal antibody recognizing p53-serine 15-phosphoryla-
tion from Cell Signaling (Waltham, MA, USA) or (ii) monoclonal
antibody to conformationally inactive Pab 240 (SC-99) (Santa Cruz
Biotechnology, Santa Cruz, CA). Detection of green ﬂuorescence
was achieved by reaction with corresponding secondary anti-
bodies conjugated to Oregon Green (Molecular Probes, Eugene, OR)
for excitation with an Argon laser. Integral contouring was done by
staining DNA with propidium iodide (Sigma–Aldrich, St. Louis, MO)
in the long red region.
3. Results
3.1. Hypoxia increases PRIMA-1 toxicity against mutant p53 SKBR3
breast cancer cells
The human epidermal growth factor receptor 2 (erbB2/HER2)
and p53 pathways may be involved in the therapeutic response of
breast cancer cells. Since PRIMA-1 is known to primarily reactivate
mutant p53, we initially investigated whether the toxicity of this
agent differed under normoxia or hypoxia against SKBR3 breast
cancer cells that endogenously harbor a mutant p53R175H gene
and over-express HER2 [27,28]. After seeding these cells overnight
in complete Dulbecco’s medium containing 20 mM glucose and10% fetal bovine serum, PRIMA-1 was added at three different
concentrations in 0.1% DMSO, adding the same vehicle to the
corresponding controls, for a 3 day exposure to normoxic or
hypoxic conditions. Crystal violet staining of surviving cells
revealed that normoxic cells were partly susceptible to 50 mM
PRIMA-1, but essentially resistant to 25 mM PRIMA-1. However,
PRIMA-1 cytotoxicity was clearly enhanced under hypoxia at all
concentrations tested, including 25 mM (Fig. 1).
3.2. Glucose-dependent SKBR3 cell survival under hypoxia in 2%
serum is counteracted by 25 mM PRIMA-1
Since tumor cells face glucose and growth factor shortage when
growing distant from sites of vascularization [1], we investigated
the response to PRIMA-1 and to nutlin-3, another p53-reactivating
small molecule [23–26] in SKBR3 cells exposed to low serum and
lower glucose concentrations [1] instead of those used for sub-
culturing proliferating tumor cells such as 20 mM glucose and 10%
fetal bovine serum. For this, we used 2% dialyzed serum with
glucose supplementation between 1.25 mM and 10 mM glucose,
adding PRIMA-1 and/or nutlin-3, at the concentrations indicated.
SKBR3 cells did not grow signiﬁcantly under physiological 5 mM
glucose in normoxia but showed viability at 10 mM glucose under
hypoxia. This was speciﬁcally counteracted by 25 mM PRIMA-1,
when used singly or together with nutlin-3, with no comparable
single response to nutlin-3 (Fig. 2A). In contrast, under normoxia,
SKBR3 cells in 2% dialyzed serum showed a glucose-dependent
survival, unaffected by PRIMA-1 even when supplemented with
nutlin-3 (Fig. 2B).
3.3. Synergism between PRIMA-1 and hypoxia leads to apoptosis-
associated PARP cleavage mediated by activation of p53-serine 15
phosphorylation
To investigate some of the mechanisms involved in the
potentiation of PRIMA-1 activation by hypoxia, we used SKBR3
cells cultured for 3 days in medium supplemented with 5%
dialyzed fetal calf serum and physiological 5 mM glucose under
Fig. 2. SKBR3 cell survival after 4 days in hypoxia and 2% serum is promoted by glucose and counteracted by 25 mM PRIMA-1. Cells were seeded overnight as quadruplicates in
Dulbecco’s medium supplemented with 20 mM glucose and 10% fetal calf serum. After extensive washing, the medium was replaced with glucose-free medium
supplemented with 2% dialyzed serum, including glucose, DMSO, PRIMA-1 in 0.1% DMSO and/or nutlin-3 in 0.1% DMSO, and cells were treated for 96 h, as indicated in each
experiment. Note that cell survival was glucose-dependent and suppressed whenever 25 mM PRIMA-1 was present under hypoxia, unless N-acetylcysteine (NAC) was present
(A). No comparable PRIMA-1 toxicity was detected when cells were exposed to the same treatments under normoxia (B).
Fig. 3. (A) Apoptosis-associated PARP cleavage induced by 25 mM PRIMA-1 in hypoxic SKBR3 cells is counterated by NAC. SKBR3 cells cultured overnight in complete medium
were extensively washed to remove serum and glucose for further culture for 72 h, under normoxia or hypoxia, in medium supplemented with 10 mM glucose and 5%
dialyzed serum in the presence of 25 mM or 50 mM PRIMA-1, including 2 mM N-acetylcysteine (NAC) whenever indicated. Cells were collected for immune blotting, to assay
the relative ratio of intact PARP to apoptosis-associated PARP fragment (indicated by small arrows). Results were normalized to relative actin levels. (B) 25 mM PRIMA-1
preferentially increases p53-serine 15-phosphorylation in hypoxic SKBR3 cells. Cells cultured as indicated above were exposed to 25 mM PRIMA-1 under hypoxia or normoxia
in medium supplemented with 10 mM glucose and 2% dialyzed serum whenever indicated, for 72 h. Subsequently, cells were ﬁxed with 4% p-formaldehyde in phosphate-
buffered saline pH 7.2 (PBS), permeabilized in 0.5% Nonidet P40 in PBS, reacted with monoclonal antibody to detect p53-serine 15-phosphorylation, followed by staining with
the respective Alexa Fluor 488–secondary antibody conjugate and the DNA ﬂuorochrome, propidium iodide, for laser scanning cytometric analysis.
M. Rieber, M. Strasberg-Rieber / Biochemical Pharmacology 84 (2012) 1563–15701566
Fig. 4. Hypoxia increases reactivity with PAb240 and counteracts resistance of wt p53 MCF-7 breast cancer cells to PRIMA-1. (A) Genetically matched MCF-7 cells differing in
p53 genotypes were seeded in quadruplicate at 1  104 cells per 96 well plate overnight in complete Dulbecco’s medium with 20 mM glucose supplemented with 10% fetal
calf serum. The following day, cells were exposed to normoxia or hypoxia (1% oxygen) for 72 h with 0.1% DMSO (controls) or PRIMA-1, nutlin-3, camptotehecin (CPT) or 2-
acetyl furanonaphtoquinone (FNQ) at the indicated concentrations in 0.1% DMSO. Live-dead analysis and DNA levels were quantitated in an isocyte laser scanning.
spectroﬂuorimeter. (B) Cells treated as above indicated were ﬁxed in 70% ethanol followed by crystal violet staining as indicated under Section 2. Note the morphological
changes induced, and the loss of cell viability in wt p53 MCF-7 cells after PRIMA-1 treatment under hypoxia. (C) Chemical hypoxia inducer CoCl2 increases reactivity with Pab
240 in wt p53 MCF-7 cells.
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50 mM PRIMA-1 to induce PARP cleavage, in contrast to 25 mM
PRIMA-1 in the corresponding hypoxic cells. The potentiation of
PRIMA-1 toxicity under hypoxia was antagonized by the anti-
oxidant N-acetylcysteine (NAC). This correlated with a greater
activation of p53-serine 15 phosphorylation [21] in hypoxic cells
exposed to 25 mM PRIMA-1 (Fig. 3B).
3.4. Hypoxia induces a conformationally inactive epitope in wt p53
MCF-7 cells and increases their susceptibility to PRIMA-1
Since PRIMA-1Met can bind to mutant p53, but it can also bind to
unfolded wt p53 implying that PRIMA-1Met could activate unfolded
wt p53 [22,19], we used laser scanning cytometry to determine
whether CoCl2, an inducer of chemical hypoxia, increased the
mutant p53 conformation in wt p53 MCF-7 ERa cells. This revealed
an increased binding of the Pab 240 monoclonal antibody directed
to a conformationally inactive p53 epitope exposed preferentially
by mutant p53 (Fig. 4C). Based on our above observations, we also
investigated whether hypoxia increased the toxicity of PRIMA-1
against MCF-7 ERa breast cancer cells, irrespective of their p53
status. For this, genetically-matched MCF-7 cells harboring wt p53
or mutant p53, were seeded overnight in complete medium with
10% fetal bovine serum, followed by a 2 day exposure to PRIMA-1,
nutlin-3, camptothecin (CPT) or 2-acetylfuranonaphthoquinone
(FNQ) [34] under normoxia or hypoxia. This revealed uniform CPT
toxicity in both cell types and resistance of mutant p53 MCF-7 cells
to FNQ. Consistent with other reports [24,25], the MDM2 inhibitor
nutlin-3 failed to promote apoptosis in normoxic MCF-7 cells,
although it is known to cause a signiﬁcant reduction in thepercentage of S-phase cells in MCF-7 cultures, at the same
concentration used in other studies [24,25]. However, it was
noteworthy that hypoxia counteracted the resistance of wt p53
MCF-7 cells to PRIMA-1, in contrast to the susceptibility of
matched mutant p53 MCF-7 cell counterparts to the same
treatment (Fig. 4A and B). In contrast, hypoxia did not enhance
nutlin-3 toxicity against genetically-matched MCF-7 cells irre-
spective of p53 status (Fig. 4A and B). In spite of the apparent
resistance of wt p53 MCF-7 cells to PRIMA-1 or nutlin-3 in
normoxia, these cells changed their normoxic epithelial morphol-
ogy when exposed to these agents, without evidence of overt
toxicity. Moreover, even without any additions, hypoxia disrupted
the typical epithelial cobblestone appearance of MCF-7 cells [30],
inducing a more mesenchymal organization (Fig. 4B). On the
contrary, hypoxic wt p53 MCF-7 cells treated with PRIMA-1
showed loss of viability (Fig. 4A and B).
3.5. PRIMA-1 increases SOD2 expression in hypoxic wt p53 MCF-7
cells
PRIMA-1 and PRIMA-1Met possibly promote an oxidative
environment in tumor cells, in which they may be converted to
compounds that form adducts with thiols in mutant p53 [22]. Since
Mn-SOD (SOD2) can protect against superoxide generated in
mitochondria, [31], we investigated whether Mn-SOD (SOD2) is
induced by hypoxia and PRIMA-1. The relative expression of Mn-
SOD (SOD2) was quantitated in wt p53 MCF-7 cells seeded in 96
well plates. After hypoxia or normoxia, including PRIMA-1
whenever indicated, ﬁxed and permeabilized cells were reacted
with a monospeciﬁc antibody which identiﬁed a single SOD2 band
Fig. 5. (A) PRIMA-1 increases SOD2 expression in hypoxic wt p53 MCF-7 cells. wt
p53 MCF-7 cultures were exposed to hypoxia in quadruplicates in 96 well plates,
including PRIMA-1 whenever indicated for 24 h. Cells were ﬁxed, permeabilized
and stained with antibody against SOD2, as indicated under Section 2. Detection
was achieved following addition of the respective Alexa Fluor 488–secondary
antibody conjugate for green staining, and propidium iodide, for DNA red staining.
The ratio of speciﬁc green ﬂuorescence normalized to red DNA ﬂuorescence was
quantitated in an isocyte laser scanning spectroﬂuorimeter. (B) SOD2 over-
expression and BSO increase PRIMA-1 toxicity against wt p53 MCF-7 cells. neo4
cells and Mn-SOD-over-expressing Mn11 cultures, originated from wt p53 MCF-7
cells [31] were seeded in sextuplicate at 1  104 cells per 96 well plate overnight in
complete Dulbecco’s medium with 20 mM glucose supplemented with 10% fetal
calf serum medium. The following day, cells under normoxia were exposed to
DMSO (controls), PRIMA-1 and BSO whenever indicated. Relative cell viability was
determined after 72 h by quantitating the cell-catalyzed conversion of non-
ﬂuorescent resazurin to ﬂuorescent resoruﬁn, as indicated under Section 2.
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unbound antibody by extensive washing, the respective Alexa
Fluor 488-conjugated secondary antibody was added to provide
green staining and propidium iodide was included to detect DNA
red staining. Quantitation of relative green SOD ﬂuorescence
versus red DNA content indicated that hypoxia and PRIMA-1,
increases SOD2 expression in wt p53 MCF-7 cells (Fig. 5A).
3.6. SOD2 over-expression and BSO increase PRIMA-1 toxicity against
wt p53 MCF-7 cells
To gain additional insight into a role for Mn-SOD in PRIMA-1
toxicity, MCF-7 neo4 cells and Mn-SOD-over-expressing Mn11
MCF-7 cells [31] were used to determine whether PRIMA-1 toxicity
under normoxia was inﬂuenced by Mn-SOD expression. This
revealed greater susceptibility to 75 mM PRIMA-1 in Mn-SOD
overexpressing Mn11 cells compared to control neo4 cells (Fig. 5B).
The role of glutathione in the response to PRIMA-1 was also
investigated by examining the response to buthionine sulfoximine
(BSO), a glutathione-depleting agent [35,36]. This showed that BSO
by itself did not affect cell viability. However, it potentiated
PRIMA-1 toxicity in both normoxic control neo4 and Mn11 cells
(Fig. 5B).
3.7. PRIMA-1 synergizes with peroxidase to promote mut p53-MCF-7
apoptosis
Since NAC counteracted the hypoxia-induced apoptosis in
SKBR3 at 25 mM PRIMA-1 (Fig. 3A), and BSO increased PRIMA-1toxicity against MCF-7 cells (Fig. 5B), this implicared redox
imbalance in PRIMA-1 toxicity, in agreement with others showing
that PRIMA-1 and PRIMA-1Met react covalently with thiol groups in
mutant p53 [22]. Hence, we investigated in mutant p53-MCF-7
cells, whether the toxicity of PRIMA-1 was modulated by
exogenous addition of either peroxidase (PRX) or superoxide
dismutase (SOD) at 250 mg/ml. Cells were cultured for 20 h in
complete Dulbecco’s medium supplemented with 10% fetal bovine
serum. Subsequently, PRX or SOD was added overnight followed by
PRIMA-1 treatment whenever indicated for 1 additional day.
Electrophoretic separation and speciﬁc immune blotting revealed
that apoptosis-associated PARP cleavage was enhanced in cells
jointly treated with PRX + PRIMA-1, although PRX also caused
some PARP cleavage. In contrast, no signiﬁcant PARP fragmenta-
tion was seen in cells jointly treated with SOD and PRIMA-1.
Maximal PARP degradation induced by PRX and PRIMA-1
correlated with a relative increase in Puma, suggestive of mutant
p53 reactivation [21] and super-induction of the mitochondrial
Mn-SOD (SOD2). This implies that Mn-SOD (SOD2) and PUMA but
not Cu–Zn-SOD (SOD1) and CCS are involved in PRIMA-1-induced
apoptosis in mutant p53 MCF-7 cells (Fig. 6).
4. Discussion
This report is the ﬁrst to show that hypoxia increases PRIMA-1
toxicity against wt p53 MCF-7 cells. In contrast, another p53-
reactivating agent, nutlin-3 that targets wt p53, was unable to
activate wt p53 MCF-7 cells even under hypoxia (Fig. 4A and B).
p53 reactivation by nutlin-3 involves interfering with the binding
of MDM2 to the p53 N-terminus. However, MDM2 and its MDMX
homolog show 80% similarity in their MDM2-p53-binding
domains [23,24]. Since nutlin-3 does not disrupt p53-MDMX
interaction, its ability to activate p53 appears compromised in
tumors over-expressing MDMX like MCF-7 cells [23,24]. One
possible mechanism to explain the hypoxia-mediated enhance-
ment of PRIMA-1 toxicity in wt p53 MCF-7 breast carcinoma cells,
is that hypoxia increases a mutant p53 conformation in these cells
[13,15] (Fig. 4C). Another novel ﬁnding was that hypoxia
increased the efﬁcacy of PRIMA-1 against mutant p53 SKBR3
cells that over-express Her2/erbB2 (Fig. 3). This hypoxia-
mediated enhancement of PRIMA-1 toxicity was counteracted
by the anti-oxidant N-acetylcysteine, implying that increased
oxidative stress under low oxygen further increases PRIMA-1
toxicity (Fig. 3A). SOD2 was increased by hypoxia and PRIMA-1 in
wt p53 MCF-7 cells (Fig. 5A), implying that these joint treatments
increased dismutation of superoxide into H2O2, in agreement with
others demonstrating a role for H2O2 in hypoxic stress [7,6]. The
importance of SOD2 in PRIMA-1 toxicity was further emphasized
when Mn-SOD (SOD2) over-expressing Mn11-MCF-7 cells showed
greater susceptibility to PRIMA-1 when compared to their neo4
control cells (Fig. 5B). This report also demonstrated that depletion
of H2O2 by exogenous peroxidase enhanced PRIMA-1 toxicity and
PUMA expression in MCF-7 cells transduced with mutant p53R175H
[30]. No comparable potentiation was seen when PRIMA-1 was used
together with exogenous SOD, implying that an imbalance in H2O2
may be more critical for the response to PRIMA-1. The fact that
peroxidase synergizes with PRIMA-1 (Fig. 6) is compatible with
results showing that distinct H2O2 concentrations are required to
promote proliferation of tumor cells [6]. It was noteworthy that the
synergism of PRIMA-1 plus exogenous peroxidase increased
expression of the p53-dependent PUMA protein [20,21], and
selectively induced the mitochondrial Mn-SOD (SOD2), possibly
by increasing oxidative imbalance (Fig. 6). These results suggest that
enzymatically diminishing exogenous H2O2 in the presence of
PRIMA-1, may further increase mitochondrial H2O2 as a result of
greater Mn-SOD expression (Fig. 6).
Fig. 6. PRIMA-1 synergizes with peroxidase to promote mut p53-MCF-7 apoptosis associated with induction of Mn-SOD and PUMA. Mutant p53-MCF-7 genetically matched
to the wt p53 MCF-7 cells, described in Fig. 5A, were cultured overnight in complete medium, followed by a 24 h exposure to PRIMA-1, peroxidase, or SOD, whenever
indicated. Subsequently, cells were harvested and subjected to electrophoretic separation and immune blotting, as indicated under Section 2. Note that apoptosis-associated
PARP cleavage (small discontinuous arrows) and induction of Mn-SOD and PUMA are potentiated by joint treatment with PRIMA-1 and peroxidase (PRX).
Fig. 7. Summary. Hypoxia, ROS and glutathione depletion increase PRIMA-1 mediated redox activation of p53.
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Taken together, these results indicate for the ﬁrst time that
PRIMA-1 toxicity against wt p53 MCF-7 cells is increased under
hypoxia. Another important ﬁnding is the enhancement of PRIMA-
1 toxicity in normoxia when these cells over-express Mn-SOD.
Glutathione depletion with BSO [35,36] did not affect the viability
of neo4 and Mn11 MCF-7 cells, but potentiated PRIMA-1 toxicity
against these cells under normoxia, irrespective of Mn-SOD over-
expression. Hypoxia apparently increases unfolding of wt p53 to a
more mutant-like conformation [13,15], which is likely to promote
susceptibility to PRIMA-1, through a redox mechanism involving
thiol groups in the p53 molecule [37] (see Fig. 7, summary).
Survival under a hypoxic microenvironment for cancer cells like
those used in this study, frequently correlates with tumor
progression [1,2], inactivation of the p53 tumor suppressor gene
[10,14,13,15] and diminished response to chemotherapy or
radiation [1]. However, since hypoxia increases the efﬁcacy of
PRIMA-1 but not that of nutlin-3 against MCF-7 cells irrespective of
p53 status, this report offers a novel therapeutic alternative to kill
hypoxic wt p53 breast cancer tumors like MCF-7 cells, known to be
resistant to other p53-reactivating agents like nutlin-3, because of
MDMX over-expression [24,25].
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